Kirkland Advises GTCR on Strategic Majority Investment in Biocoat
Kirkland & Ellis advised GTCR on its strategic majority investment in Biocoat, Incorporated (Biocoat), a leading medical device contract manufacturing organization. As part of its Leaders Strategy™ to find and partner with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions, GTCR will partner with industry veteran Chip Hance, the current Chairman of GTCR portfolio company Regatta Medical Holdings, LLC (d/b/a Resonetics), who will join Biocoat as Executive Chairman. Going forward, the existing Biocoat management team, led by CEO Jim Moran, will continue in their existing roles executing on Biocoat's growth initiatives in partnership with GTCR.
The Kirkland team was led by corporate partners Sandy Perl, Michael Weed, Chris Thomas and Neil Vohra and associates Zoe Quick, Lisa Gunter and Jessica Lowe; debt finance partners Christopher Butler, Tom Dobleman and Patrick Loughery and associates Alex Straka and Chris Smiciklas; and tax partner Polina Liberman and associate David Gilbert.
